5 Key Takeaways From Bristol Myers Squibb's Second-Quarter Earnings Call
Bristol Myers Squibb (NYSE: BMY) began 2020 with a lot of products that it didn't have a year ago thanks to the giant Celgene deal that closed last November. The company's second-quarter earnings report on Thursday was seen as positive even though the company lost $1.48 per share during the three months ended June 30, 2020.
Bristol Myers Squibb's quarterly updates weren't simple before the company integrated Celgene's operations. If you don't want to dig through all the details, here are five key takeaways investors should understand.
Image source: Getty Images.
Source Fool.com
